HCW Biologics Says Q1 2026 Financial Statements Should No Longer Be Relied Upon; Error In Two-Class Method For EPS Calculation Identified; Errors Constitute Material Misstatement Of EPS; EPS Of $2.19 Per Share Overstated By $0.80 Per Share For Q1 2026; Material Weakness In Technical Accounting Review Control Identified
On August 10, 2026, the Audit Committee of the Board of Directors (the "Audit Committee") of HCW Biologics Inc. (the "Company"), in consultation with management and the Company’s independent registered